Treatment of chronic lymphocytic B-leukemia (B-CLL) with human IL-2 [interleukin-2] and CD40 ligand and plasmid gene modified autologous tumor cells (CLIPA)

Trial Profile

Treatment of chronic lymphocytic B-leukemia (B-CLL) with human IL-2 [interleukin-2] and CD40 ligand and plasmid gene modified autologous tumor cells (CLIPA)

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2010

At a glance

  • Drugs Chronic lymphocytic leukaemia vaccine (Primary)
  • Indications Leukaemia
  • Focus Adverse reactions
  • Acronyms CLIPA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Apr 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 27 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top